Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

Cancer Chemotherapy and Pharmacology
James J LeeJan H Beumer

Abstract

TAS-102 is an oral fluoropyrimidine prodrug composed of trifluridine (FTD) and tipiracil hydrochloride (TPI) in a 1:0.5 ratio. FTD is a thymidine analog, and it is degraded by thymidine phosphorylase (TP) to the inactive trifluoromethyluracil (FTY) metabolite. TPI inhibits degradation of FTD by TP, increasing systemic exposure to FTD. Patients with advanced solid tumors (6 M/2 F; median age 58 years; PS 0-1) were enrolled on this study. Patients in group A (N = 4) received 60 mg TAS-102 with 200 nCi [(14)C]-FTD, while patients in group B (N = 4) received 60 mg TAS-102 with 1000 nCi [(14)C]-TPI orally. Plasma, blood, urine, feces, and expired air (group A only) were collected up to 168 h and were analyzed for (14)C by accelerator mass spectrometry and analytes by LC-MS/MS. FTD: 59.8% of the (14)C dose was recovered: 54.8% in urine mostly as FTY and FTD glucuronide isomers. The extractable radioactivity in the pooled plasma consisted of 52.7% FTD and 33.2% FTY. TPI: 76.8% of the (14)C dose was recovered: 27.0% in urine mostly as TPI and 49.7% in feces. The extractable radioactivity in the pooled plasma consisted of 53.1% TPI and 30.9% 6-HMU, the major metabolite of TPI. Absorbed (14)C-FTD was metabolized and mostly excreted in ur...Continue Reading

References

Mar 1, 1981·Clinical Pharmacology and Therapeutics·R A HamiltonB J Kline
Jan 1, 1993·Life Sciences·L Z BenetE T Lin
May 22, 2002·Therapeutic Drug Monitoring·Maria ShipkovaUNKNOWN German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Franck DesmoulinRobert Martino
Jan 25, 2006·Clinical Pharmacokinetics·Jan H BeumerJan H M Schellens
Jun 6, 2008·Investigational New Drugs·Michael J OvermanJames L Abbruzzese
Sep 18, 2008·Cancer Investigation·Michael J OvermanJames L Abbruzzese
Apr 1, 2007·Drug Metabolism Letters·F DesmoulinM Malet-Martino
Jan 8, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lian ZhouRamaswamy A Iyer
Apr 20, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jianyao WangRasmy Talaat
May 24, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard A GrahamCornelis E C A Hop
Mar 22, 2014·The Journal of Biological Chemistry·Jan Terje AndersenJason Cameron
May 15, 2015·The New England Journal of Medicine·Robert J MayerUNKNOWN RECOURSE Study Group

❮ Previous
Next ❯

Citations

May 18, 2016·Drug Metabolism Reviews·C M NijenhuisJ H Beijnen
Oct 12, 2016·Chemical Research in Toxicology·Heather A EnrightKenneth W Turteltaub
Sep 7, 2019·Drugs·Connie KangEmma D Deeks
Aug 29, 2016·Drugs·Celeste B Burness, Sean T Duggan
Jul 31, 2019·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Betty M ChanHeinz-Josef Lenz
Apr 21, 2020·Drug Design, Development and Therapy·Nadda Muhamad, Kesara Na-Bangchang
Jan 14, 2021·Japanese Journal of Clinical Oncology·Takayuki YoshinoKei Muro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.